BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 32998095)

  • 1. Pathophysiological mechanisms underlying MAFLD.
    Kuchay MS; Choudhary NS; Mishra SK
    Diabetes Metab Syndr; 2020; 14(6):1875-1887. PubMed ID: 32998095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperation of liver cells in health and disease.
    Kmieć Z
    Adv Anat Embryol Cell Biol; 2001; 161():III-XIII, 1-151. PubMed ID: 11729749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors.
    Khanmohammadi S; Ramos-Molina B; Kuchay MS
    Diabetes Metab Syndr; 2023 Jul; 17(7):102788. PubMed ID: 37302383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of hedgehog ligands in human simple steatosis may protect against nonalcoholic steatohepatitis: Is TAZ a crucial regulator?
    Khajehahmadi Z; Mohagheghi S; Nikeghbalian S; Geramizadeh B; Khodadadi I; Karimi J; Ghaffari ME; Tavilani H
    IUBMB Life; 2019 Sep; 71(9):1382-1390. PubMed ID: 31087761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis.
    Vacca M; Leslie J; Virtue S; Lam BYH; Govaere O; Tiniakos D; Snow S; Davies S; Petkevicius K; Tong Z; Peirce V; Nielsen MJ; Ament Z; Li W; Kostrzewski T; Leeming DJ; Ratziu V; Allison MED; Anstee QM; Griffin JL; Oakley F; Vidal-Puig A
    Nat Metab; 2020 Jun; 2(6):514-531. PubMed ID: 32694734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway.
    Ni XX; Li XY; Wang Q; Hua J
    J Physiol Biochem; 2021 Feb; 77(1):35-45. PubMed ID: 33188625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
    Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
    Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Ibrahim SH; Hirsova P; Gores GJ
    Gut; 2018 May; 67(5):963-972. PubMed ID: 29367207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetramethylpyrazine reduces glucose and insulin-induced activation of hepatic stellate cells by inhibiting insulin receptor-mediated PI3K/AKT and ERK pathways.
    Zhang F; Zhang Z; Kong D; Zhang X; Chen L; Zhu X; Lu Y; Zheng S
    Mol Cell Endocrinol; 2014 Jan; 382(1):197-204. PubMed ID: 24071517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
    Kjær MB; George J; Kazankov K; Grønbæk H
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.
    Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palmitic acid elicits hepatic stellate cell activation through inflammasomes and hedgehog signaling.
    Duan NN; Liu XJ; Wu J
    Life Sci; 2017 May; 176():42-53. PubMed ID: 28322865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
    Geng Y; Faber KN; de Meijer VE; Blokzijl H; Moshage H
    Hepatol Int; 2021 Feb; 15(1):21-35. PubMed ID: 33548031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice.
    Tomita K; Teratani T; Suzuki T; Shimizu M; Sato H; Narimatsu K; Okada Y; Kurihara C; Irie R; Yokoyama H; Shimamura K; Usui S; Ebinuma H; Saito H; Watanabe C; Komoto S; Kawaguchi A; Nagao S; Sugiyama K; Hokari R; Kanai T; Miura S; Hibi T
    Hepatology; 2014 Jan; 59(1):154-69. PubMed ID: 23832448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.
    Wang X; Zheng Z; Caviglia JM; Corey KE; Herfel TM; Cai B; Masia R; Chung RT; Lefkowitch JH; Schwabe RF; Tabas I
    Cell Metab; 2016 Dec; 24(6):848-862. PubMed ID: 28068223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis.
    Pulli B; Ali M; Iwamoto Y; Zeller MW; Schob S; Linnoila JJ; Chen JW
    Antioxid Redox Signal; 2015 Dec; 23(16):1255-69. PubMed ID: 26058518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro.
    Mahli A; Seitz T; Beckröge T; Freese K; Thasler WE; Benkert M; Dietrich P; Weiskirchen R; Bosserhoff A; Hellerbrand C
    Cells; 2019 May; 8(5):. PubMed ID: 31096638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.